Intellectia LogoIntellectia
Product
Resources
Stock
Crypto
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategy
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns

Resources

Learn
Blog
Earnings
Tutorial
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
StockCryptoPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MLTX
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
MLTX
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

MLTX Similar Chart Price Prediction

The price of MLTX is predicted to go up 2.76%, based on the high correlation periods with INTG. The similarity of these two price pattern on the periods is 93.31%.

stocks logo

MLTX

stocks logo

INTG

Up: 2.76%Similarity: 93.31%

MLTX Revenue Forecast

MLTX EPS Forecast

MLTX FAQs

What is bull’s view on MLTX?

MLTX stock is currently trading at $41.83, with analysts projecting a target price of $76.85, indicating a potential upside of 63.12%. The bullish view is driven by optimism surrounding its hidradenitis suppurativa asset, Sonelokimab, which could deliver enhanced mid-2025 data. Additionally, its strong cash position of $448 million supports ongoing R&D and operational growth.

What is bear's view on MLTX?

MLTX stock is currently trading at $41.83, with bearish indicators such as RSI (14) at 40.60 and MACD showing a negative divergence (-1.47). The stock is below its 20-day SMA ($43.38), suggesting downward momentum, and its Bollinger Bands indicate limited upside near $48.60. Additionally, MoonLake's rising net losses ($121.2M in 2024) and declining cash reserves signal financial strain, which could pressure the stock further.

MLTX VS S&P500

Ask Intellectia about MLTX

MLTX Analyst's Forecast

Yun Zhong

Wedbush

Buy

2024-11-05

Price Target

$92 → $73

Upside

+53.26%

Wedbush analyst Yun Zhong assumed coverage of MoonLake Immunotherapeutics with an Outperform rating and price target of $73, down from $92. The company's single asset sonelokimab is an IL-17 inhibitor "with unique features that support strong differentiation," the analyst tells investors in a research note. The firm sees "strong potential" for sonelokimab in a multi -billion market that continues to expand.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI Screener
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free

Hot Stocks

stocks logo

CATY

Cathay General Bancorp

$47.595
1.37%
stocks logo

HL

Hecla Mining Co

$5.19
1.17%
stocks logo

IMVT

Immunovant Inc

$19.1
-7.28%
stocks logo

SMPL

Simply Good Foods Co

$37.9
0.40%
stocks logo

USLM

United States Lime & Minerals Inc

$92.63
-1.30%
stocks logo

OR

Osisko Gold Royalties Ltd

$18.135
-1.06%
stocks logo

CRSP

CRISPR Therapeutics AG

$44.0911
0.39%
stocks logo

CLSK

CleanSpark Inc

$8.13
1.75%
stocks logo

EE

Excelerate Energy Inc

$30.235
-1.45%
stocks logo

CRNX

Crinetics Pharmaceuticals Inc

$36.16
1.06%